EndoTAG-1. MediGene.
MediGene is developing EndoTAG-1, a formulation of paclitaxel encapsulated in positively charged lipid-based complexes, for the potential treatment of cancer. Phase II clinical trials in patients with advanced pancreatic cancer are ongoing.
Schuch
Gunter
G
University Hospital Hamburg - Eppendorf, Department of Medicine - Oncology and Hematology, Martinstr 52, D-20246, Hamburg, Germany. schuch@uke.uni-hamburg.de
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008081:Liposomes; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000098:blood supply / Q000188:drug therapy*
D000972:Antineoplastic Agents, Phytogenic; D008081:Liposomes; D017239:Paclitaxel